Yoshibayashi Hiroshi, Ishiguro Hiroshi, Kawaguchi Kanako, Yamoto Mako, Nishimura Tomomi, Yamada Harumi, Namura Maki, Nishio Naoko, Nakamura Kyouhei, Shimada Koutarou, Ono Kazuo, Kato Hiroaki
Dept. of Breast Surgery, Japanease Red Cross Society of Wakayama Medical Center, Japan.
Gan To Kagaku Ryoho. 2013 May;40(5):627-9.
A 49-year-old woman visited our hospital presentind with a right breast lump. She underwent core needle biopsy, and her disease was diagnosed as breast cancer(invasive ductal carcinoma, ER slightly positive, PgR and HER2 negative). We chose neoadjuvant chemotherapy because the tumor size was over 3 cm in diameter with a histological grade III, and she asked to have her breast conserved. Because she had an allergy to alcohol, we treated her with FEC100 followed by Abraxane(260mg/ m2)q3W for 4 courses. After chemotherapy, she received breast conserving therapy. During the treatment with Abraxane, the patient was very well and showed no major side effects except for grade 3 neutropenia was found on an outpatient basis. After chemotherapy, breast MRI detected no invasive lesion. Pathological examination showed pCR. We concluded that Abraxane was a good option as neoadjuvant chemotherapy for early breast cancer.
一名49岁女性因右乳肿块前来我院就诊。她接受了粗针活检，疾病被诊断为乳腺癌（浸润性导管癌，雌激素受体略阳性，孕激素受体和人表皮生长因子受体2阴性）。由于肿瘤直径超过3 cm且组织学分级为III级，并且她要求保留乳房，我们选择了新辅助化疗。因为她对酒精过敏，我们先给予FEC100方案治疗，随后每3周给予白蛋白结合型紫杉醇（260mg/m²），共4个疗程。化疗后，她接受了保乳治疗。在使用白蛋白结合型紫杉醇治疗期间，患者情况良好，除门诊发现3级中性粒细胞减少外，未出现其他严重副作用。化疗后，乳腺磁共振成像未检测到浸润性病变。病理检查显示达到病理完全缓解。我们得出结论，白蛋白结合型紫杉醇作为早期乳腺癌新辅助化疗是一个不错的选择。
